PETACH TIKVA, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in the following three investor conferences:
H.C. Wainwright 26th Annual Global Investment Conference
PolyPid’s presentation will be available on-demand beginning on Monday, September 9, 2024, at 7:00 AM ET and throughout the conference, via the conference platform.
Lytham Partners Fall 2024 Investor Conference
PolyPid’s fireside chat will be available on-demand beginning on Tuesday, October 1, 2024, via the conference platform and for 90 days thereafter on the Lytham investor portal.
Sidoti & Company Micro-Cap Virtual Conference
Conference Date: November 13-14, 2024
The PolyPid management team will participate in one-on-one investor meetings during these events. Investors interested in meeting with PolyPid at the conferences should contact the appropriate conference directly.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.95 |
| Daily Change: | -0.18 -5.75 |
| Daily Volume: | 10,560 |
| Market Cap: | US$20.060M |
December 11, 2024 November 13, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
